These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38918644)

  • 1. Vincristine and CYP3A5 Genetic Polymorphism in Rhabdomyosarcoma: Comment.
    Daungsupawong H; Wiwanitkit V
    Asian Pac J Cancer Prev; 2024 Jun; 25(6):1861-1862. PubMed ID: 38918644
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and Toxicity of Vincristine and CYP3A5 Genetic Polymorphism in Rhabdomyosarcoma Pediatric Egyptian Patients.
    Shalaby N; Zaki HF; Badary OA; Kamal S; Nagy M; Makhlouf D; Elnashar A; Elnadi E; Abdelshafi SA; Abouelnaga S; Saber MM
    Asian Pac J Cancer Prev; 2024 Apr; 25(4):1391-1409. PubMed ID: 38680001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of CYP3A5 Expression and Vincristine Neurotoxicity in Pediatric Malignancies in Turkish Population.
    Kayilioğlu H; Kocak U; Kan Karaer D; Percin EF; Sal E; Tekkesin F; Isik M; Oner N; Belen FB; Yilmaz Keskin E; Okur A; Albayrak M; Kaya Z; Pinarli FG; Yenicesu I; Karadeniz C; Oguz A; Gursel T
    J Pediatr Hematol Oncol; 2017 Aug; 39(6):458-462. PubMed ID: 28697165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approach.
    Moore AS; Norris R; Price G; Nguyen T; Ni M; George R; van Breda K; Duley J; Charles B; Pinkerton R
    J Paediatr Child Health; 2011 Dec; 47(12):875-82. PubMed ID: 21658147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of Genetic Polymorphism of CYP3A5 to Cyclophosphamide Efficacy and Toxicity in Rhabdomyosarcoma Pediatric Egyptian Cancer Patients.
    ElShereef CE; Zaki HF; Badary OA; Kamal S; Nagy M; Makhlouf D; Kamal M; Elnadi I; A Abdelshafi S; Abou El Naga S; Saber MM
    Asian Pac J Cancer Prev; 2024 Jul; 25(7):2445-2455. PubMed ID: 39068579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia.
    Egbelakin A; Ferguson MJ; MacGill EA; Lehmann AS; Topletz AR; Quinney SK; Li L; McCammack KC; Hall SD; Renbarger JL
    Pediatr Blood Cancer; 2011 Mar; 56(3):361-7. PubMed ID: 21225912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity.
    Guilhaumou R; Solas C; Bourgarel-Rey V; Quaranta S; Rome A; Simon N; Lacarelle B; Andre N
    Cancer Chemother Pharmacol; 2011 Dec; 68(6):1633-8. PubMed ID: 21968951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apparent high CYP3A5 expression is required for significant metabolism of vincristine by human cryopreserved hepatocytes.
    Dennison JB; Mohutsky MA; Barbuch RJ; Wrighton SA; Hall SD
    J Pharmacol Exp Ther; 2008 Oct; 327(1):248-57. PubMed ID: 18650247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Paratesticular rhabdomyosarcoma].
    Méndez Gallart R; Gómez Tellado M; Montero Sánchez M; Arnáiz Peña S; Vela Nieto D; País Piñeiro E
    Actas Urol Esp; 1999 Jun; 23(6):549-52. PubMed ID: 10464968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of race on the CYP3A-mediated metabolism of vincristine in pediatric patients with acute lymphoblastic leukemia.
    Sims RP
    J Oncol Pharm Pract; 2016 Feb; 22(1):76-81. PubMed ID: 25305360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vincristine Disposition and Neurotoxicity Are Unchanged in Humanized CYP3A5 Mice.
    Li Y; Kazuki Y; Drabison T; Kobayashi K; Fujita KI; Xu Y; Jin Y; Ahmed E; Li J; Eisenmann ED; Baker SD; Cavaletti G; Sparreboom A; Hu S
    Drug Metab Dispos; 2024 Jan; 52(2):80-85. PubMed ID: 38071551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Polymorphisms of CYP3A5 gene in acute leukemia patients and their role in chemotherapy and prognosis].
    Shen LJ; Chen FY; Wang T; Wang HR; Zhong JH; Han JY; Ouyang RR
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):26-30. PubMed ID: 18315894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative study of polymorphism frequencies of the CYP2D6, CYP3A5, CYP2C8 and IL-10 genes in Mexican and Spanish women with breast cancer.
    Alcazar-González GA; Calderón-Garcidueñas AL; Garza-Rodríguez ML; Rubio-Hernández G; Escorza-Treviño S; Olano-Martin E; Cerda-Flores RM; Castruita-Avila AL; González-Guerrero JF; le Brun S; Simon-Buela L; Barrera-Saldaña HA
    Pharmacogenomics; 2013 Oct; 14(13):1583-92. PubMed ID: 24088129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The management of advanced rhabdomyosarcoma of the upper eyelid.
    Wolter JR; O'Malley ER
    J Pediatr Ophthalmol Strabismus; 1978; 15(5):303-5. PubMed ID: 24877354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a less toxic vinca alkaloid derivative for use as a chemotherapeutic agent, based on in silico structural insights and metabolic interactions with CYP3A4 and CYP3A5.
    Saba N; Seal A
    J Mol Model; 2018 Mar; 24(4):82. PubMed ID: 29502215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paratesticular Rhabdomyosarcoma Associated with Tuberculosis.
    Sari N; Okur N; Uçmak G; Ilhan IE
    J Trop Pediatr; 2017 Apr; 63(2):160-162. PubMed ID: 27686557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation.
    Kniepeiss D; Renner W; Trummer O; Wagner D; Wasler A; Khoschsorur GA; Truschnig-Wilders M; Tscheliessnigg KH
    Clin Transplant; 2011; 25(1):146-50. PubMed ID: 20041908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Relationship between the CYP3A5 genetic polymorphism and susceptibility to and prognosis of childhood acute leukemia].
    Huang Z; Chai YH; Cen JN
    Zhonghua Er Ke Za Zhi; 2007 Jul; 45(7):546-8. PubMed ID: 17953817
    [No Abstract]   [Full Text] [Related]  

  • 19. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group.
    Pappo AS; Lyden E; Breitfeld P; Donaldson SS; Wiener E; Parham D; Crews KR; Houghton P; Meyer WH;
    J Clin Oncol; 2007 Feb; 25(4):362-9. PubMed ID: 17264331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of CYP3A5 genetic polymorphism on pharmacokinetics of tacrolimus in healthy Japanese subjects.
    Suzuki Y; Homma M; Doki K; Itagaki F; Kohda Y
    Br J Clin Pharmacol; 2008 Jul; 66(1):154-5. PubMed ID: 18341670
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.